Skip to main content
Top
Published in: Rheumatology International 12/2010

01-11-2010 | Original Article

RETRACTED ARTICLE: Correlation of ESR, C3, C4, anti-DNA and lupus activity based on British Isles Lupus Assessment Group Index in patients of rheumatology clinic

Authors: Siavash Nasiri, Mansoor Karimifar, Zahra Sayed Bonakdar, Mansour Salesi

Published in: Rheumatology International | Issue 12/2010

Login to get access

Abstract

This study aimed to determine the correlation between of ESR, C3, C4, anti-DNA, and lupus activity and also the construct and criterion validity of the British Isles Lupus Assessment Group (BILAG) index for assessing disease activity in systemic lupus erythematosus (SLE). Patients with SLE were recruited into a cross-sectional study. Data were analyzed for estimating of SLE disease activity [scores on the BILAG index and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)]. Overall BILAG scores were determined by the highest score achieved in any of the individual systems in the respective index. Erythrocyte sedimentation rates (ESRs), C3 levels, C4 levels, anti-double-stranded DNA (anti-dsDNA) levels, and SLEDAI-2K scores were used in the analysis of construct validity. Statistical analyses were performed using ordinal logistic regression for construct validity. Of the 100 patients with SLE, 90% were women. Their mean ± SD age was 31.1 ± 9.8 years. Increasing overall scores on the BILAG index were associated with increasing ESRs, decreasing C3 levels, decreasing C4 levels, elevated anti-dsDNA levels, and increasing SLEDAI-2K scores (all P < 0.01). These findings show that the ESR, C3, C4, and anti-DNA should be used in the evaluation and management of patients with SLE. Also the results show that the BILAG index has construct validity.
Literature
1.
go back to reference Liang MH, Socher SA, Roberts WN, Esdaile JM (1988) Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum 31:817–825CrossRefPubMed Liang MH, Socher SA, Roberts WN, Esdaile JM (1988) Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum 31:817–825CrossRefPubMed
2.
go back to reference Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN et al (2005) BILAG 2004: development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 44:902–906CrossRef Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN et al (2005) BILAG 2004: development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 44:902–906CrossRef
3.
go back to reference Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML et al (1993) The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 86:447–458PubMed Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML et al (1993) The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 86:447–458PubMed
4.
go back to reference Yee CS, Farewell V, Isenberg DA, Prabu A, Sokoll K, Teh LS et al (2006) Revised British Isles Lupus Assessment Group 2004 Index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum 54:3300–3305CrossRefPubMed Yee CS, Farewell V, Isenberg DA, Prabu A, Sokoll K, Teh LS et al (2006) Revised British Isles Lupus Assessment Group 2004 Index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum 54:3300–3305CrossRefPubMed
5.
go back to reference Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRefPubMed Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRefPubMed
6.
go back to reference Hochberg MC (1997) For the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725CrossRefPubMed Hochberg MC (1997) For the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725CrossRefPubMed
7.
go back to reference Gladman DD, Ibanez D, Urowitz MB (2002) Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 29:288–291PubMed Gladman DD, Ibanez D, Urowitz MB (2002) Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 29:288–291PubMed
8.
go back to reference Williams RL (2000) A note on robust variance estimation for clustercorrelated data. Biometrics 56:645–646CrossRefPubMed Williams RL (2000) A note on robust variance estimation for clustercorrelated data. Biometrics 56:645–646CrossRefPubMed
9.
go back to reference Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH et al (2002) Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 46:995–1002CrossRefPubMed Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH et al (2002) Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 46:995–1002CrossRefPubMed
10.
go back to reference Davies EJ, Hillarby MC, Cooper RG, Hay EM, Green JR, Shah S et al (1993) HLA-DQ, DR and complement C4 variants in systemic lupus erythematosus. Br J Rheumatol 32:870–875CrossRefPubMed Davies EJ, Hillarby MC, Cooper RG, Hay EM, Green JR, Shah S et al (1993) HLA-DQ, DR and complement C4 variants in systemic lupus erythematosus. Br J Rheumatol 32:870–875CrossRefPubMed
11.
go back to reference Price P, Witt C, Allcock R, Sayer D, Garlepp M, Kok CC et al (1999) The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev 167:257–274CrossRefPubMed Price P, Witt C, Allcock R, Sayer D, Garlepp M, Kok CC et al (1999) The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev 167:257–274CrossRefPubMed
12.
go back to reference Schotte H, Willeke P, Tidow N, Domschke W, Assmann G, Gaubitz M et al (2005) Extended haplotype analysis reveals an association of TNF polymorphisms with susceptibility to systemic lupus erythematosus beyond HLA-DR3. Scand J Rheumatol 34:114–121CrossRefPubMed Schotte H, Willeke P, Tidow N, Domschke W, Assmann G, Gaubitz M et al (2005) Extended haplotype analysis reveals an association of TNF polymorphisms with susceptibility to systemic lupus erythematosus beyond HLA-DR3. Scand J Rheumatol 34:114–121CrossRefPubMed
13.
go back to reference Hartung K, Ehrfeld H, Lakomek HJ, Coldewey R, Lang B, Krapf F, SLE Study Group et al (1992) The genetic basis of Ro and La antibody formation in systemic lupus erythematosus. Results of a multicenter study. Rheumatol Int 11:243–249CrossRefPubMed Hartung K, Ehrfeld H, Lakomek HJ, Coldewey R, Lang B, Krapf F, SLE Study Group et al (1992) The genetic basis of Ro and La antibody formation in systemic lupus erythematosus. Results of a multicenter study. Rheumatol Int 11:243–249CrossRefPubMed
14.
go back to reference Provost TT, Talal N, Bias W, Harley JB, Reichlin M, Alexander EL (1988) Ro(SS-A) positive Sjögren’s/lupus erythematosus (SC/LE) overlap patients are associated with the HLA-DR3 and/or DRw6 phenotypes. J Invest Dermatol 914:369–371CrossRef Provost TT, Talal N, Bias W, Harley JB, Reichlin M, Alexander EL (1988) Ro(SS-A) positive Sjögren’s/lupus erythematosus (SC/LE) overlap patients are associated with the HLA-DR3 and/or DRw6 phenotypes. J Invest Dermatol 914:369–371CrossRef
15.
go back to reference Batchelor JR, Fielder AH, Walport MJ, David J, Lord DK, Davey N et al (1987) Family study of the major histocompatibility complex in HLA DR3 negative patients with systemic lupus erythematosus. Clin Exp Immunol 70:364–371PubMedPubMedCentral Batchelor JR, Fielder AH, Walport MJ, David J, Lord DK, Davey N et al (1987) Family study of the major histocompatibility complex in HLA DR3 negative patients with systemic lupus erythematosus. Clin Exp Immunol 70:364–371PubMedPubMedCentral
16.
go back to reference Guzman J, Cardiel MH, Arce-Salinas A, Sanchez-Guerrero J, Alarcon-Segovia D (1992) Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 19:1551–1558PubMed Guzman J, Cardiel MH, Arce-Salinas A, Sanchez-Guerrero J, Alarcon-Segovia D (1992) Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 19:1551–1558PubMed
17.
go back to reference Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D et al (1992) Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol 19:608–611PubMed Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D et al (1992) Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol 19:608–611PubMed
18.
go back to reference Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D et al (1994) Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation. J Rheumatol 21:1468–1471PubMed Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D et al (1994) Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation. J Rheumatol 21:1468–1471PubMed
19.
go back to reference Wollaston SJ, Farewell VT, Isenberg DA, Gordon C, Merrill JT, Petri MA et al (2004) Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. J Rheumatol 31:2390–2394PubMed Wollaston SJ, Farewell VT, Isenberg DA, Gordon C, Merrill JT, Petri MA et al (2004) Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. J Rheumatol 31:2390–2394PubMed
20.
go back to reference Davas EM, Tsirogianni A, Karamitsos D, Economoida I, Dantis PC (1999) Serum IL-6, TNF α, P55sr TNFα, P75sr TNFα, sr IL-2α level and disease activity in SLE. Clin Rheumatol 18:17–22CrossRefPubMed Davas EM, Tsirogianni A, Karamitsos D, Economoida I, Dantis PC (1999) Serum IL-6, TNF α, P55sr TNFα, P75sr TNFα, sr IL-2α level and disease activity in SLE. Clin Rheumatol 18:17–22CrossRefPubMed
Metadata
Title
RETRACTED ARTICLE: Correlation of ESR, C3, C4, anti-DNA and lupus activity based on British Isles Lupus Assessment Group Index in patients of rheumatology clinic
Authors
Siavash Nasiri
Mansoor Karimifar
Zahra Sayed Bonakdar
Mansour Salesi
Publication date
01-11-2010
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 12/2010
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1201-3

Other articles of this Issue 12/2010

Rheumatology International 12/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine